ARTICLE | Company News
MabCampath approved in EU
July 12, 2001 7:00 AM UTC
Millennium (MLNM) and Ilex Oncology (ILXO) received European marketing approval for their MabCampath anti- CD52 monoclonal antibody to treat B cell chronic lymphocytic leukemia (B-CLL) in patients who...